Atossa Genetics Inc Total Liabilities
Atossa Genetics Inc total liabilities. Based on the latest financial reports, Atossa Genetics Inc (ATOS) has total liabilities worth $8.22 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Atossa Genetics Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Atossa Genetics Inc (2009–2024)
Total liabilities of Atossa Genetics Inc from 2009 to 2024. This chart illustrates how Atossa Genetics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Atossa Genetics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Atossa Genetics Inc Competitors by Total Liabilities
The table below lists competitors of Atossa Genetics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JPEL Private Equity Ltd
LSE:JPEL
|
UK | $537.00K |
|
DAYTHREE DIGITAL BERHAD
KLSE:0281
|
Malaysia | RM20.52 Million |
|
Delta Resources Ltd
V:DLTA
|
Canada | CA$2.19 Million |
|
Egeplast Ege Plastik Ticaret ve Sanayi AS
IS:EPLAS
|
Turkey | TL921.98 Million |
|
Guandian Defense Technology Co. Ltd. A
SHG:688287
|
China | CN¥111.81 Million |
|
Eagon Ind
KO:008250
|
Korea | ₩211.26 Billion |
|
Acrinova AB Series B
ST:ACRI-B
|
Sweden | Skr457.03 Million |
|
Next Hydrogen Solutions Inc.
V:NXH
|
Canada | CA$17.47 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Atossa Genetics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Atossa Genetics Inc assets under control.
Liquidity & Leverage Metrics
Atossa Genetics Inc Total Liabilities Ratios Explained
Atossa Genetics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Atossa Genetics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Atossa Genetics Inc (2009–2024)
The table below shows the annual total liabilities of Atossa Genetics Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.97 Million | -5.14% |
| 2023-12-31 | $5.24 Million | -5.96% |
| 2022-12-31 | $5.57 Million | +78.12% |
| 2021-12-31 | $3.13 Million | -80.06% |
| 2020-12-31 | $15.68 Million | +1065.77% |
| 2019-12-31 | $1.34 Million | -53.88% |
| 2018-12-31 | $2.92 Million | +137.92% |
| 2017-12-31 | $1.23 Million | +17.01% |
| 2016-12-31 | $1.05 Million | -58.14% |
| 2015-12-31 | $2.50 Million | +10.40% |
| 2014-12-31 | $2.27 Million | +61.00% |
| 2013-12-31 | $1.41 Million | -14.73% |
| 2012-12-31 | $1.65 Million | +9.15% |
| 2011-12-31 | $1.51 Million | +74.44% |
| 2010-12-31 | $866.86K | +1511.84% |
| 2009-12-31 | $53.78K | -- |
About Atossa Genetics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develop… Read more